Guillermo Lerzo
About
Guillermo Lerzo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Guillermo Lerzo has authored 20 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Guillermo Lerzo's work include Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Guillermo Lerzo is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Guillermo Lerzo collaborates with scholars based in Argentina, United States and France. Guillermo Lerzo's co-authors include Linda T. Vahdat, Xavier Pivot, Gabriel N. Hortobágyi, Edith A. Perez, Eva Thomas, Henri Roché, Hyun Cheol Chung, Luis Fein, Linda D. Bosserman and Brian P. Mullaney and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.
In The Last Decade
Guillermo Lerzo
20 papers receiving 880 citations
Peers
Guillermo Lerzo
Valorie F. Chan United States
David Edward Lebwohl United States
U. Klaassen Germany
Rubina Qamar United States
Rubi K. Li Philippines
Kenichi Harano Japan
Herb Kotz United States
S. Bartholomeus Belgium
J.-M. Nabholtz Canada
M. Piccart Belgium
Citations per year, relative to Guillermo Lerzo Guillermo Lerzo (= 1×)
peers
Valorie F. Chan
Countries citing papers authored by Guillermo Lerzo
Since
Specialization
Citations
This map shows the geographic impact of Guillermo Lerzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillermo Lerzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillermo Lerzo more than expected).
Fields of papers citing papers by Guillermo Lerzo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Guillermo Lerzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillermo Lerzo. The network helps show where Guillermo Lerzo may publish in the future.
Co-authorship network of co-authors of Guillermo Lerzo
This figure shows the co-authorship network connecting the top 25 collaborators of Guillermo Lerzo. A scholar is included among the top collaborators of Guillermo Lerzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillermo Lerzo. Guillermo Lerzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Muniz, David Queiroz Borges, Hongbo Yang, James Signorovitch, et al.. (2019). Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. Advances in Therapy. 36(12). 3446–3457.
2.
Rugo, Hope S., Henri Roché, Eva Thomas, et al.. (2018). Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clinical Breast Cancer. 18(6). 489–497.
3.
Yardley, Denise A., Sara A. Hurvitz, Masakazu Toi, et al.. (2017). Abstract P4-22-13: Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1. Cancer Research. 77(4_Supplement). P4–22.
4.
Isaacs, Claudine, Ruth O’Regan, Binghe Xu, et al.. (2016). Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3. Cancer Research. 76(4_Supplement). P4–13.
5.
Gómez, Henry, Silvia P. Neciosup, C. Tosello, et al.. (2015). A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clinical Breast Cancer. 16(1). 38–44.
6.
Llombart‐Cussac, Antonio, Marc Espié, Anantbhushan Ranade, et al.. (2014). Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in the first-line treatment of anthracycline pretreated advanced breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 1011–1011.
7.
Gómez, Henry, Silvia P. Neciosup, C. Tosello, et al.. (2013). Abstract P4-12-26: A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane (LACOG 0801). Cancer Research. 73(24_Supplement). P4–12.
8.
Gómez, Henry, Silvia P. Neciosup, C. Tosello, et al.. (2012). A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801 / EGF111792).. Journal of Clinical Oncology. 30(15_suppl). e11087–e11087.
9.
Radbruch, Lukas, L. M. Torres, John Ellershaw, et al.. (2011). Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Supportive Care in Cancer. 20(3). 565–573.
10.
Hortobágyi, Gabriel N., Henry Gómez, Rubi K. Li, et al.. (2010). Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment. 122(2). 409–418.
11.
Buzaid, Antônio C., Sérgio D. Simon, Luis Fein, et al.. (2010). Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study. Clinical Colorectal Cancer. 9(5). 282–289.
12.
Rugo, HS, Hoffmann-La Roche, Kim T. Blackwell, et al.. (2009). Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.. Cancer Research. 69(2_Supplement). 3057–3057.
13.
Buzaid, Antônio C., Sérgio D. Simon, Luis Fein, et al.. (2007). Preliminary data from a phase II study of cetuximab with irinotecan in heavily pretreated patients with epidermal growth factor (EGFR)-expressing metastatic colorectal cancer (mCRC): LABEL. Journal of Clinical Oncology. 25(18_suppl). 14521–14521.
14.
Thomas, E. Donnall, Henry Gómez, Rubi K. Li, et al.. (2007). Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology. 25(33). 5210–5217.
15.
Fein, Luis, Julia Hidalgo, Guillermo Lerzo, et al.. (2007). 3055 POSTER Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) progressing on or after prior irinotecan therapy: final results of the LABEL study. European Journal of Cancer Supplements. 5(4). 252–253.
16.
Perez, Edith A., Guillermo Lerzo, Xavier Pivot, et al.. (2007). Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 25(23). 3407–3414.
17.
Thomas, E. Donnall, Edith A. Perez, P. Mukhopadhyay, et al.. (2006). Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. Journal of Clinical Oncology. 24(18_suppl). 660–660.
18.
Ibarra, Jorge E., et al.. (2004). Gemcitabine (GEM) + oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB) + paclitaxel (PAC): Preliminary report of a phase II study. Journal of Clinical Oncology. 22(14_suppl). 5111–5111.
19.
Lerzo, Guillermo. (2002). Gemcitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Evaluation of response toxicity. European Journal of Cancer. 38(11). S74–S74.
20.
Richardet, Eduardo, E. Mickiewicz, Guillermo Lerzo, et al.. (1999). Uracil/tegafur plus oral calcium folinate in advanced breast cancer.. PubMed. 13(7 Suppl 3). 96–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Valorie F. Chan Breakdown of academic impact, for papers by David Edward Lebwohl Breakdown of academic impact, for papers by U. Klaassen Breakdown of academic impact, for papers by Rubina Qamar Breakdown of academic impact, for papers by Rubi K. Li Breakdown of academic impact, for papers by Kenichi Harano Breakdown of academic impact, for papers by Herb Kotz Breakdown of academic impact, for papers by S. Bartholomeus Breakdown of academic impact, for papers by J.-M. Nabholtz Breakdown of academic impact, for papers by M. Piccart